vTv Therapeutics (NASDAQ:VTVT) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS

vTv Therapeutics (NASDAQ:VTVT) posted its quarterly earnings data on Thursday. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.08), Zacks reports.

vTv Therapeutics Trading Up 2.2%

Shares of vTv Therapeutics stock traded up $0.76 on Friday, reaching $35.37. 147,517 shares of the company were exchanged, compared to its average volume of 55,695. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The firm has a market capitalization of $139.36 million, a price-to-earnings ratio of -38.03 and a beta of 0.28. The stock has a fifty day moving average price of $33.36 and a 200-day moving average price of $34.80.

Wall Street Analyst Weigh In

VTVT has been the subject of a number of research analyst reports. Zacks Research downgraded vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. BTIG Research lifted their price target on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. HC Wainwright dropped their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday. Wall Street Zen upgraded vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Rodman & Renshaw initiated coverage on vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, vTv Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $55.83.

Hedge Funds Weigh In On vTv Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new stake in shares of vTv Therapeutics in the fourth quarter valued at $221,000. 683 Capital Management LLC purchased a new position in shares of vTv Therapeutics during the fourth quarter valued at $731,000. Finally, Geode Capital Management LLC boosted its stake in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares during the period. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.